Article ID Journal Published Year Pages File Type
5890756 Bone 2012 6 Pages PDF
Abstract
► Risedronate significantly increases lumbar spine BMD from baseline after 4 years of treatment. ► Patients switching from placebo to 2 years of risedronate treatment show a significant increase in lumbar spine BMD from baseline. ► Few new vertebral and clinical fractures occurred during this open-label extension. ► There were no significant differences in BTMs between the two groups at months 36 and 48. ► Safety results continued to show that risedronate was well-tolerated in men with osteoporosis.
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Developmental Biology
Authors
, , , , , ,